BASEL, Switzerland, Feb. 10 /CNW Telbec/ - Neuro-Biotech Corp.
(PINKSHEET: MRES) (OTCQB: MRES) Dr Claude Poulin is pleased to announce
that on February 9, MRES has received an unsolicited offer for the
purchase of all the outstanding shares at $0.15 per share.
Management is currently conducting due diligence and should be able to
provide to its shareholders further details by Tuesday February 15. The
company making the offer, with expertise similar to Neuro-Biotech, is
exclusively contracted by military forces to research and develop new
type of medications.
For more information on Neuro-Biotech Corp or to contact a company
representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe
Harbor Provisions of the Private Securities Litigation Act of 1995.
Certain statements in this press release may contain words such as
"anticipates," "believes," "could," "expects," "intends," "may,"
"projects," "targets" and other similar language that is considered
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties and persons reading this
release are cautioned that such statements are only predictions, and
that the Company's actual future results or performance may be
materially different. The Company disclaims any intention or obligation
to update or revise forward-looking information, whether as a result of
new information, future events, or otherwise, could cause the company's
actual results to differ materially from those indicated in any
SOURCE Neuro-Biotech Corp.
For further information:
Dr. Claude Poulin
41 61 500 05 16